Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks, and under the breasts.
The hidradenitis suppurativa drugs in development report provides an overview of the hidradenitis suppurativa pipeline landscape. The report provides comprehensive information on the therapeutics under development for hidradenitis suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for hidradenitis suppurativa and features dormant and discontinued projects.
What are the targets of the hidradenitis suppurativa pipeline drugs market?
The targets of the hidradenitis suppurativa pipeline drugs market are Tumor Necrosis Factor, Complement C5, Interleukin 1 Alpha, Interleukin 1 Receptor Like 2, Interleukin 17A, Interleukin 23 Subunit Alpha, Tyrosine Protein Kinase JAK1, Interleukin 1 Receptor Associated Kinase 4, Phosphodiesterase 4, Tumor Necrosis Factor Receptor Superfamily Member 5, and others.
Hidradenitis suppurativa pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the hidradenitis suppurativa pipeline drugs market?
The mechanisms of action of the hidradenitis suppurativa pipeline drugs market are Tumor Necrosis Factor Inhibitor, Complement C5 Inhibitor, Interleukin 1 Alpha Inhibitor, Interleukin 1 Receptor Like 2 Antagonist, Interleukin 17A Inhibitor, Interleukin 23 Subunit Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Phosphodiesterase 4 Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and others.
Hidradenitis suppurativa pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the hidradenitis suppurativa pipeline drugs market?
The routes of administration in the hidradenitis suppurativa pipeline drugs market are subcutaneous, intravenous, oral, and topical.
Hidradenitis suppurativa pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
For more routes of administration insights, download a free report sample
The molecule types in the hidradenitis suppurativa pipeline drugs market are monoclonal antibody, small molecule, fusion protein, monoclonal antibody conjugated, and synthetic peptide.
Hidradenitis suppurativa pipeline drugs market, by molecule types
For more molecule types insights, download a free report sample
Which are the key companies in the hidradenitis suppurativa pipeline drugs market?
Some of the key companies in the hidradenitis suppurativa pipeline drugs market are Novartis AG, AbbVie Inc, Acelyrin Inc, Aclaris Therapeutics Inc, Afecta Pharmaceuticals Inc, Alvotech ehf, Amgen Inc, AnaptysBio Inc, AstraZeneca Plc, Attillaps Holdings Inc, Azora Therapeutics Australia Pty Ltd, BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, ChemoCentryx Inc, and CSL Ltd.
Hidradenitis suppurativa pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
Targets | Tumor Necrosis Factor, Complement C5, Interleukin 1 Alpha, Interleukin 1 Receptor Like 2, Interleukin 17A, Interleukin 23 Subunit Alpha, Tyrosine Protein Kinase JAK1, Interleukin 1 Receptor Associated Kinase 4, Phosphodiesterase 4, and Tumor Necrosis Factor Receptor Superfamily Member 5 |
Mechanisms of Action | Tumor Necrosis Factor Inhibitor, Complement C5 Inhibitor, Interleukin 1 Alpha Inhibitor, Interleukin 1 Receptor Like 2 Antagonist, Interleukin 17A Inhibitor, Interleukin 23 Subunit Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Phosphodiesterase 4 Inhibitor, and Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist |
Routes of Administration | Subcutaneous, Intravenous, Oral, and Topical |
Molecule Types | Monoclonal Antibody, Small Molecule, Fusion Protein, Monoclonal Antibody Conjugated, and Synthetic Peptide |
Key Companies | AbbVie Inc, Acelyrin Inc, Aclaris Therapeutics Inc, Afecta Pharmaceuticals Inc, Alvotech ehf, Amgen Inc, AnaptysBio Inc, AstraZeneca Plc, Attillaps Holdings Inc, Azora Therapeutics Australia Pty Ltd, BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, ChemoCentryx Inc, and CSL Ltd |
This report provides:
- A snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
- Reviews of pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
- Evaluation of Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Acelyrin Inc
Aclaris Therapeutics Inc
Afecta Pharmaceuticals Inc
Alvotech ehf
Amgen Inc
AnaptysBio Inc
AstraZeneca Plc
Attillaps Holdings Inc
Azora Therapeutics Australia Pty Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
ChemoCentryx Inc
CSL Ltd
Eli Lilly and Co
Ichnos Sciences Inc
Immunwork Inc
Incyte Corp
InflaRx NV
Inmagene Biopharmaceuticals Ltd
Innovation Pharmaceuticals Inc
Johnson & Johnson
Jubilant Therapeutics Inc
Kiniksa Pharmaceuticals Ltd
Kymera Therapeutics, Inc
Lytix Biopharma AS
NeuClone Pty Ltd
NovaRock Biotherapeutics Inc
Novartis AG
Pfizer Inc
Pharmapraxis
Phoenicis Therapeutics Inc
Regranion LLC
Rigel Pharmaceuticals Inc
Staidson (Beijing) Biopharmaceuticals Co Ltd
UCB SA
Union Therapeutics AS
VYNE Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the hidradenitis suppurativa pipeline drugs market?
The key targets of the hidradenitis suppurativa pipeline drugs market are Tumor Necrosis Factor, Complement C5, Interleukin 1 Alpha, Interleukin 1 Receptor Like 2, Interleukin 17A, Interleukin 23 Subunit Alpha, Tyrosine Protein Kinase JAK1, Interleukin 1 Receptor Associated Kinase 4, Phosphodiesterase 4, Tumor Necrosis Factor Receptor Superfamily Member 5, and others.
-
What are the key mechanisms of action of the hidradenitis suppurativa pipeline drugs market?
The key mechanisms of action of the hidradenitis suppurativa pipeline drugs market are Tumor Necrosis Factor Inhibitor, Complement C5 Inhibitor, Interleukin 1 Alpha Inhibitor, Interleukin 1 Receptor Like 2 Antagonist, Interleukin 17A Inhibitor, Interleukin 23 Subunit Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Phosphodiesterase 4 Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and others.
-
What are the key routes of administration in the hidradenitis suppurativa pipeline drugs market?
The key routes of administration in the hidradenitis suppurativa pipeline drugs market are subcutaneous, intravenous, oral, and topical.
-
What are the key molecule types in the hidradenitis suppurativa pipeline drugs market?
The key molecule types in the hidradenitis suppurativa pipeline drugs market are monoclonal antibody, small molecule, fusion protein, monoclonal antibody conjugated, and synthetic peptide.
-
Which are the key companies in the hidradenitis suppurativa pipeline drugs market?
Some of the key companies in the hidradenitis suppurativa pipeline drugs market are AbbVie Inc, Acelyrin Inc, Aclaris Therapeutics Inc, Afecta Pharmaceuticals Inc, Alvotech ehf, Amgen Inc, AnaptysBio Inc, AstraZeneca Plc, Attillaps Holdings Inc, Azora Therapeutics Australia Pty Ltd, BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, ChemoCentryx Inc, and CSL Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.